Osteomodulin Antibodies

Osteomodulin (OMD)

May be implicated in biomineralization processes. Has a function in binding of osteoblasts through the alpha(V)beta(3)- integrin (By similarity).

. .

Gene Information

Human
Gene Name:	OMD
Uniprot:	Q99983
Entrez:	4958

Family

Belongs to:
small leucine-rich proteoglycan (SLRP) family

Alternative Names

Keratan sulfate proteoglycan osteomodulin; KSPG osteomodulin; OMD; OSAD; osteoadherin proteoglycan; Osteoadherin; osteomodulin; SLRR2C; SLRR2Costeoadherin

Molecular Weight

Mass (kDA):
49.492 kDA

Genomic Context

Human
Location:	9q22.31
Sequence:	9; NC_000009.12 (92414245..92424554, complement)

Tissue Specificity

Bone specific.

Subcellular Localizations

Secreted, extracellular space, extracellular matrix.

Diseases

• Dystrophy
• Dystonia Disorders
• Mental Disorders
• Age Related Macular Degeneration
• Parkinson Disease
• Meige Syndrome
• Movement Disorders
• Depressive Disorder
• Deglutition Disorders
• Myeloproliferative Syndrome, Transient
• Delirium, Dementia, Amnestic, Cognitive Disorders

• Pain
• Spasm
• Polyps
• Hemorrhage
• Blepharoptosis

Pathways

• Fermentation
• Aging
• Cell Activation
• B Cell Activation
• Embryo Development
• Glycosylation
• Oocyte Maturation
• Localization
• Drug Resistance
• Cytokine Production
• Pathogenesis
• Excretion
• Cell Migration

• Osteoblast Differentiation
• Rumination
• Immune Response
• Eating Behavior
• Hypersensitivity
• Inflammatory Response
• Chemotaxis

PTMs

• Glycosylation
• Reduction

• Acetylation
• Methylation

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/OMD

Boster Bio - The Best Uses Of The OMD Marker

In this article, we will discuss the advantages and uses of the Anti-Osteomodulin OMD Antibody and its High-affinity primary antibody. This product is also an invaluable tool for assessing a wide range biological functions. It is easily accessible by all scientists around world. There are some things to be aware of before buying the OMD Marker. Here are the top uses of OMD Marker.

Anti-Osteomodulin OMD Antibody

When looking for an anti-Osteomodulin antibody, Boster Bio has a wide variety of options. These antibodies have been tested in ELISA, WB and react with both mouse Osteomodulin protein and human. The manufacturer also offers a rabbit anti-Osteomodulin antibody. Research on osteoporosis can be greatly enhanced by the use of antibodies to Osteomodulin.

This antibody was developed by the company’s team of researchers. It is highly specific for Osteoadherin, and is available in 96 well plates. The ELISA kits can be used with different types of samples and can measure Osteomodulin concentrations in serum or cell culture supernatants. It has a sensitivities of 50 pg/ml. It is also formulated to detect Osteoadherin up to 50%. The manufacturer recommends that you only use small amounts of the samples for one-time use. It is important to store samples in a way that does not allow for repeated freeze-thaw cycles.

High-affinity primary antibodies

A high-affinity prima antibody is an antibody with a specificity greater that 90%. Because it can detect OMD-tagged antibodies, the OMD marker was used in this study. The marker is a highly immunogenic peptide that binds with a specific cell receptor. It has also been shown that it can be used to identify the targets of many therapies.

OMD protein is expressed by osteoblasts and plays a key role in osteogenesis. It has been demonstrated that mature OMD protein interacts and clusters with BMP2 cytokine, promoting BMP2/SMAD sign transduction. OMD has been suggested as a target gene for SMAD4, which is a crucial protein in the BMP/SMAD signaling pathway. It could be used as a positive coordinator in osteogenic differentiation.

The OMD protein is a component of the extracellular matrix (ECM), which is composed of various proteins. LRRs, or leukocyte receptor repeat like domains, are the distinctive features of OMD's core protein. LRRs act in binding sites for the ligands. These motifs are common in solenoid structures which use a concave area for binding. Therefore, mutations in LRRs may alter the protein/ligand affinity.

OMD interaction with BMP2 was determined in hDPSCs by immunoblot analysis and immunoprecipitation. hDPSCs were transfected respectively with HA–BMP2 and Flag-OMD truncates. The primary antibodies were then used for blotting the lysates. This experiment was conducted using a BioTek microplate reader.

The interaction of OMD with BMP2 through a common pathway was explored in depth. Strong binding was seen in the coIP of OMD and BMP2 ectopically produced. OMD and BMP2 interactions can also be blocked by blocking BMP I receptors. Scientists were able to identify the LRRs responsible by OMD in 293T cells that are ectopicly expressed. One of the findings showed that a mutant lacking the tenth LRR or the eleventh LRR had significant impaired interactions with BMP2 proteins.

OMD marker offers many advantages in the production of high-affinity antibody. In addition to its ability to detect OMD-tagged antigens, it also offers many other benefits for immunohistochemistry. It has a high affinity as well as a high level of specificity. A high-affinity primary antibody elutes well from affinity columns and is less prone to cross-reactivity and background. OMD markers are also useful in the production of monoclonal high-affinity antibodies.

Recently, the OMD marker was identified as a candidate to detect osteomodulin in bones. This class II keratan sulfur sulfate (SLRP) plays a crucial role in the development and maintenance of bone tissues. It has also been reported to be upregulated by BMP2 and linked to osteoblast cell growth. This study aims at evaluating the effectiveness of OMD markers in osteoporosis research.

The OMD Marker's benefits

One of the benefits of using the OMD Marker in radiation oncology is that it allows physicians to easily and accurately identify patients during treatments. ESTRO (the European Society for Radiotherapy and Oncology), and ASTRO, the American Society for Radiation Oncology, collaborated in developing a consensus standard for identifying and treating cancer patients. These organizations commissioned a panel of clinical experts from the US and Europe to review the current state of patient identification and treatment.

OMD is a diagnostic tool to identify metastases. It helps physicians differentiate between oligometastases and synchronous ovarian cancer. OMD is defined in different clinical situations. sOMD occurs during the initial NSCLC diagnoses. rOMD is a condition that develops when local control is not optimal. pOMD refers to the progression of disease at a limited number of metastatic sites.